NCT05907330

Phase 2 Study of CU104 in Moderate-Severe Ulcerative Colitis

A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 2 Study to Evaluate the Efficacy and Safety of CU104 in Patients With Moderate to Severe Ulcerative Colitis

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 45 (estimated)
• Sponsor: Curacle Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The study is designed to investigate efficacy and safety of CU104 in patients with moderate to severe ulcerative colitis.

Conditions

• Ulcerative Colitis

Interventions

Type	Name	Description
DRUG	CU104	CU104 will administer the study drug once a day after a meal
DRUG	Placebo	Placebo will administer the study drug once a day after a meal

Timeline

• Start date: 2024-06-01
• Primary completion: 2026-02-28
• Completion: 2026-03-31
• First posted: 2023-06-18
• Last updated: 2023-06-18

Regulatory

• FDA-regulated drug study